In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.86 below Alpha Teknova Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 6 other companies have achieved higher Quick Ratio than Alpha Teknova Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 1250, from total ranking in the second quarter 2026 at 1427.

Explain Quick Ratio?
How much Cash & cash equivalents TKNO�s has?
What are TKNO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TKNO/financial-strength

https://api.csimarket.com/api/v1/companies/TKNO/fundamentals

https://api.csimarket.com/api/v1/companies/TKNO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

TKNO Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	76.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-25.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.86	Subscribe	Subscribe	Subscribe	Subscribe
TKNO's Total Ranking	# 1250	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	29.89 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-5.02 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 7
Healthcare Sector	# 517
Overall Market	# 1466

Quick Ratio Statistics
High	Average	Low
4.38	2.82	0.83
(Sep 30 2025)		(Jun 30 2023)

Financial Statements
Alpha Teknova Inc 's Current Liabilities	$ 9 Millions	Visit TKNO's Balance sheet
Alpha Teknova Inc 's Cash & cash equivalent	$ 17 Millions	Visit TKNO's Balance sheet
Source of TKNO's Sales		Visit TKNO's Sales by Geography

Cumulative Alpha Teknova Inc 's Quick Ratio

TKNO's Quick Ratio for the trailling 12 Months

TKNO Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	1.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-28.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	2.42	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3829	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	14.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-7.06 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to TKNO Financial Strength Comparisons >> Go to Compare TKNO Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $8.93 millions, cumulative Quick Ratio decreased to 2.42 below the Alpha Teknova Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Alpha Teknova Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3810 to 3829.

Explain Quick Ratio?
How much Cash & cash equivalents TKNO�s has?
What are TKNO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 880
Within the Market	# 3829

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.35	2.52	0.39
(Dec 31 2025)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Lantheus Holdings Inc	1.98	$ 683.610 Millions	$ 345.967 Millions
Alpha Teknova Inc	1.86	$ 16.560 Millions	$ 8.926 Millions
Biomerica Inc	0.96	$ 2.733 Millions	$ 2.837 Millions
Myriad Genetics Inc	0.78	$ 107.100 Millions	$ 137.600 Millions

Date modified: 2026-11-06T13:05:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.